Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 8.01 (Other Events). Proposed underwritten public offering signals near-term equity financing and potential shareholder dilution.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Proposed underwritten public offering signals near-term equity financing and potential shareholder dilution
- Existing at-the-market sales agreement suspended during the offering process
- No further Sales Agreement stock sales until a new SEC prospectus or supplement is filed
- Financing activity may strengthen liquidity for Allogene’s operations and clinical programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.